MX2015008757A - Formulaciones de lorazepam de liberacion controlada. - Google Patents

Formulaciones de lorazepam de liberacion controlada.

Info

Publication number
MX2015008757A
MX2015008757A MX2015008757A MX2015008757A MX2015008757A MX 2015008757 A MX2015008757 A MX 2015008757A MX 2015008757 A MX2015008757 A MX 2015008757A MX 2015008757 A MX2015008757 A MX 2015008757A MX 2015008757 A MX2015008757 A MX 2015008757A
Authority
MX
Mexico
Prior art keywords
release
lorazepam
controlled release
release formulations
dosing
Prior art date
Application number
MX2015008757A
Other languages
English (en)
Spanish (es)
Inventor
Michael Vachon
Douglas A Saltel
Original Assignee
Edgemont Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015008757(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Edgemont Pharmaceuticals Llc filed Critical Edgemont Pharmaceuticals Llc
Publication of MX2015008757A publication Critical patent/MX2015008757A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
MX2015008757A 2013-01-09 2014-01-09 Formulaciones de lorazepam de liberacion controlada. MX2015008757A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750792P 2013-01-09 2013-01-09
US201361762836P 2013-02-08 2013-02-08
PCT/US2014/010863 WO2014110248A1 (fr) 2013-01-09 2014-01-09 Formulations à libération contrôlée de lorazépam

Publications (1)

Publication Number Publication Date
MX2015008757A true MX2015008757A (es) 2016-02-05

Family

ID=50030512

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008757A MX2015008757A (es) 2013-01-09 2014-01-09 Formulaciones de lorazepam de liberacion controlada.

Country Status (16)

Country Link
EP (1) EP2943186A1 (fr)
JP (1) JP2016504391A (fr)
KR (1) KR20150127037A (fr)
CN (1) CN105188682A (fr)
AU (1) AU2014205356A1 (fr)
BR (1) BR112015016322A8 (fr)
CA (1) CA2897313A1 (fr)
CL (1) CL2015001921A1 (fr)
HK (1) HK1213803A1 (fr)
IL (1) IL239778A0 (fr)
MX (1) MX2015008757A (fr)
PE (1) PE20151431A1 (fr)
PH (1) PH12015501533A1 (fr)
RU (1) RU2015128914A (fr)
SG (1) SG11201505352RA (fr)
WO (1) WO2014110248A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7110366B2 (ja) 2017-11-01 2022-08-01 エッジモント・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー・トラスト ロラゼパムのアルコール耐性経口用医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL298071A (fr) 1963-06-04
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3786813A (en) 1972-12-27 1974-01-22 Alza Corp Drug delivery device with self actuated mechanism for retaining device in selected area
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
JPS61501511A (ja) * 1984-03-21 1986-07-24 アメリカン・ホ−ム・プロダクツ・コ−ポレイション 徐放性医薬カプセル
US4624847A (en) 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
CA2431205C (fr) 2000-12-05 2005-08-23 Alexander Macgregor Systeme de distribution hydrostatique regulee d'un agent
EP1414416A4 (fr) 2001-07-10 2007-06-27 Teva Pharma Systeme d'administration de medicament permettant l'administration de medicament d'ordre zero, biphasique d'ordre zero, ascendante ou descendante
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
BR0302017B1 (pt) * 2003-06-02 2014-10-29 Ems Sigma Pharma Ltda Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos
WO2006088305A1 (fr) * 2005-02-15 2006-08-24 Chong Kun Dang Pharmaceutical Corp. Comprime mono-matrice de liberation controlee a retention gastrique

Also Published As

Publication number Publication date
CN105188682A (zh) 2015-12-23
IL239778A0 (en) 2015-08-31
AU2014205356A1 (en) 2015-07-30
CA2897313A1 (fr) 2014-07-17
WO2014110248A1 (fr) 2014-07-17
CL2015001921A1 (es) 2015-12-18
EP2943186A1 (fr) 2015-11-18
PE20151431A1 (es) 2015-09-23
JP2016504391A (ja) 2016-02-12
BR112015016322A2 (pt) 2017-07-11
PH12015501533A1 (en) 2015-10-05
HK1213803A1 (zh) 2016-07-15
RU2015128914A (ru) 2017-02-14
BR112015016322A8 (pt) 2018-01-23
KR20150127037A (ko) 2015-11-16
SG11201505352RA (en) 2015-08-28

Similar Documents

Publication Publication Date Title
HRP20181364T1 (hr) Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci
MY161022A (en) Dexmedetomidine premix formulation
IL271352B (en) A pharmaceutical preparation containing a derivative of glutarimide and its use in the treatment of eosinophilic diseases
GB201222455D0 (en) Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
PH12015502556A1 (en) Modified release formulation
HK1222337A1 (zh) 用於施加藥物活性成分或化妝品活性成分的局部組合物和載體
MX2015016410A (es) Esteres de acidos oligo-hidroxicarboxilicos y uso de los mismos.
CY1123933T1 (el) Σκευασματα παρατεταμενης αποδεσμευσης λοραζεπαμης
PH12015501533A1 (en) Controlled release formulations of lorazepam
HK1219063A1 (zh) 包含透明質酸的藥物組合物用於治療黑椎間盤疾病
HK1204967A1 (en) Composition containing natural plant extracts as active ingredients, external skin preparation comprising the same, cosmetic preparation comprising the same and pharmaceutical preparation comprising the same
MX2015009077A (es) Composicion estable que contiene fingolimod.
PH12015500070A1 (en) Pediatric oral liquid compositions containing nepadutant
MX2015011099A (es) Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos.
MX2015011101A (es) Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos.
AR094391A1 (es) Formulaciones de lorazepam de liberación sostenida
UA99891C2 (ru) Производные метил-3-(3-r-6-r-имидазо[1,2-а]пиридин-2-ил)акрилата и способ их получения
IN2013MU03639A (fr)
IN2013MU02111A (fr)
TH1401007652A (th) อะมิโนไตรอะโซโลไพริดีนสำหรับการใช้ในการรักษาการอักเสบ และองค์ประกอบทางเภสัชกรรมของมัน
UA53217U (en) Mask for therapy and general health improvement